Goldman Sachs’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-1,472,527
| Closed | -$516K | – | 7325 |
|
|
2016
Q3 | $516K | Buy |
1,472,527
+1,239,275
| +531% | +$434K | ﹤0.01% | 5019 |
|
|
2016
Q2 | $109K | Buy |
233,252
+192,812
| +477% | +$90.1K | ﹤0.01% | 6086 |
|
|
2016
Q1 | $55K | Buy |
40,440
+1,445
| +4% | +$1.97K | ﹤0.01% | 6383 |
|
|
2015
Q4 | $57K | Sell |
38,995
-61,703
| -61% | -$90.2K | ﹤0.01% | 6480 |
|
|
2015
Q3 | $159K | Buy |
100,698
+19,366
| +24% | +$30.6K | ﹤0.01% | 6165 |
|
|
2015
Q2 | $138K | Sell |
81,332
-106,851
| -57% | -$181K | ﹤0.01% | 6434 |
|
|
2015
Q1 | $262K | Sell |
188,183
-74,646
| -28% | -$104K | ﹤0.01% | 5767 |
|
|
2014
Q4 | $397K | Buy |
262,829
+88,724
| +51% | +$134K | ﹤0.01% | 5499 |
|
|
2014
Q3 | $359K | Sell |
174,105
-68,191
| -28% | -$141K | ﹤0.01% | 5593 |
|
|
2014
Q2 | $741K | Buy |
242,296
+217,885
| +893% | +$666K | ﹤0.01% | 4985 |
|
|
2014
Q1 | $61K | Buy |
24,411
+23,056
| +1,702% | +$57.6K | ﹤0.01% | 6521 |
|
|
2013
Q4 | $7K | Sell |
1,355
-151,928
| -99% | -$785K | ﹤0.01% | 6597 |
|
|
2013
Q3 | $349K | Sell |
153,283
-217,545
| -59% | -$495K | ﹤0.01% | 5456 |
|
|
2013
Q2 | $823K | Buy |
+370,828
| New | +$823K | ﹤0.01% | 4551 |
|
Goldman Sachs's RXII Position: Q4 2016 in Review
Goldman Sachs sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 1,472,527 shares — an estimated $516K sold.
Goldman Sachs first reported a position in RXII in Q2 2013 and held it in 14 quarters. The position peaked at $823K in Q2 2013. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Goldman Sachs reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Goldman Sachs sold 1,472,527 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $516K.
- Goldman Sachs first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 14 quarters.
- Goldman Sachs's GALENA BIOPHARMA INC COM position peaked at $823K in Q2 2013.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Goldman Sachs's 13F filing for Q4 2016, filed 14 Feb 2017.